- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Evaluation of Immunohistochemical Expression of C-MYC, BCL2, and BCL6 in High Grade B-cell Lymphoma | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 2, April 2026, Pages 76-81 PDF (1.81 M) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2026.166057.2485 | ||
| Authors | ||
| Raghad Salem Hanna* ; Zahraa Marwan Shaban Al-omar; Mustafa Salah Fadhil Kachachi | ||
| Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq. | ||
| Abstract | ||
| Background: High-grade B-cell lymphoma (HGBCL) is characterized by chromosomal rearrangements involving specific oncogenes. The most commonly identified oncogenes in B-cell lymphomas are MYC, BCL2, and BCL6. Translocations involving these genes are associated with aggressive tumor behavior and poor clinical outcomes. In these lymphomas, the MYC gene is involved in one rearrangement, while BCL2 and, less commonly, BCL6 participate in additional rearrangements. Objectives: To evaluate the immunohistochemical expression of C-MYC, BCL2, and BCL6 markers in HGBCL cases, as well as to determine the percentage of double-hit and triple-hit lymphoma among HGBCL cases. Materials and methods: Immunohistochemical investigations were conducted for biopsies of 70 selected cases of HGBCL, using the three markers of C-MYC, BCL2, and BCL6. Also, CD20 in conjunction with CD3 was performed for all cases to confirm their B-cell origin. Results: Out of 70 HGBCL patients, C-MYC alteration was expressed in 41% of cases. Eighty-three percent of them expressed BCL2, whereas BCL6 was expressed in 64% of cases. Conversely the double expression of C-MYC/BCL2 was established in 3 cases only (2.1%), while the C-MYC/BCL6 expression was found in 6 cases (4.2%). Most cases of double-hit lymphoma (MYC/BCL2 and MYC/BCL6) occurred in males (67% and 83%, respectively), whereas triple-hit cases were more common in females (61.1%). Conclusion: Regular evaluation of C-MYC, BCL2, and BCL6 expression by immunohistochemistry is fundamental for pathological assessment, risk stratification, and therapeutic planning for affected patients. | ||
| Keywords | ||
| High grade B-cell lymphoma; Double hit lymphoma, Triple hit lymphoma | ||
| References | ||
|
[1] L. de Leval and E. S. Jaffe, "Lymphoma classification," The Cancer Journal, vol. 26, no. 3, pp. 176-185, 2020.
[2] R. Alaggio et al., "The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms," Leukemia, vol. 36, no. 7, pp. 1720-1748, 2022.
[3] S. Susanibar‐Adaniya and S. K. Barta, "2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management," American journal of hematology, vol. 96, no. 5, pp. 617-629, 2021.
[4] X. Shi, H. Zhuo, Y. Du, K. Nyhan, J. Ioannidis, and J. D. Wallach, "Environmental risk factors for non-Hodgkin's lymphoma: umbrella review and comparison of meta-analyses of summary and individual participant data," BMJ medicine, vol. 1, no. 1, p. e000184, 2022.
[5] M. Taybi et al., "Diffuse Large B Cell Lymphoma: Immunohistochemical Classification According to Hans Algorithm and Association With Outcome in A Moroccan Institution," Clinical Pathology, vol. 17, p. 2632010X241289778, 2024.
[6] P. Yimpak, K. Bumroongkit, A. Tantiworawit, T. Rattanathammethee, S. Aungsuchawan, and T. Daroontum, "Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand," Plos one, vol. 19, no. 7, p. e0307253, 2024.
[7] B.-J. Chen, F. Fend, E. Campo, and L. Quintanilla-Martinez, "Aggressive B-cell lymphomas—from morphology to molecular pathogenesis," Annals of Lymphoma, vol. 3, 2019.
[8] L. Nguyen, P. Papenhausen, and H. Shao, "The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects," Genes, vol. 8, no. 4, p. 116, 2017.
[9] J. Choi and S. Crotty, "Bcl6-mediated transcriptional regulation of follicular helper T cells (TFH)," Trends in immunology, vol. 42, no. 4, pp. 336-349, 2021.
[10] C. Mlynarczyk, L. Fontán, and A. Melnick, "Germinal center‐derived lymphomas: The darkest side of humoral immunity," Immunological reviews, vol. 288, no. 1, pp. 214-239, 2019.
[11] S. Li et al., "BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies," Journal of Cancer, vol. 10, no. 2, p. 530, 2019.
[12] P. Sesques and N. A. Johnson, "Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements," Blood, The Journal of the American Society of Hematology, vol. 129, no. 3, pp. 280-288, 2017.
[13] C. M. Adams, S. Clark-Garvey, P. Porcu, and C. M. Eischen, "Targeting the Bcl-2 family in B cell lymphoma," Frontiers in oncology, vol. 8, p. 636, 2019.
[14] M. Klanova and P. Klener, "BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas," Cancers, vol. 12, no. 4, p. 938, 2020.
[15] A. V. Hoffbrand, Hoffbrand's essential haematology. John Wiley & Sons, 2024.
[16] W. Huang et al., "MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas," Modern Pathology, vol. 31, no. 9, pp. 1470-1478, 2018.
[17] C.-C. Tsai et al., "High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements is predominantly BCL6-rearranged and BCL6-expressing in Taiwan," Cancers, vol. 13, no. 7, p. 1620, 2021.
[18] D. S. D. A. Salam, E. E. Thit, S. H. Teoh, S. Y. Tan, S. C. Peh, and S.-C. Cheah, "C-MYC, BCL2 and BCL6 translocation in B-cell non-Hodgkin lymphoma cases," Journal of Cancer, vol. 11, no. 1, p. 190, 2020.
[19] M. G. Cardenas, E. Oswald, W. Yu, F. Xue, A. D. MacKerell Jr, and A. M. Melnick, "The expanding role of the BCL6 oncoprotein as a cancer therapeutic target," Clinical Cancer Research, vol. 23, no. 4, pp. 885-893, 2017.
[20] H. M. Mahmoud and Y. N. El-Sakhawy, "Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma," Hematology reports, vol. 3, no. 3, p. e26, 2011.
[21] P. Holmqvist, M. Lundström, O. Stål, and S.-E. S. B. C. GROUP, "Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer," The International journal of biological markers, vol. 14, no. 2, pp. 84-91, 1999.
[22] H. Kim, H.-J. Kim, and S.-H. Kim, "Diagnostic approach for double-hit and triple-hit lymphoma based on immunophenotypic and cytogenetic characteristics of bone marrow specimens," Annals of laboratory medicine, vol. 40, no. 5, pp. 361-369, 2020.
[23] S. H. Swerdlow, "Diagnosis of ‘double hit’diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC," Hematology 2014, the American Society of Hematology Education Program Book, vol. 2014, no. 1, pp. 90-99, 2014.
[24] P. A. Haddad, S. Gupta, A. Gupta, and C. Graham, "Double/Triple Hit Lymphoma Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database," Blood. Vol. 142(Supp 1), pp. 6298, 2023.
[25] P. A. Riedell and S. M. Smith, "Double hit and double expressors in lymphoma: definition and treatment," Cancer, vol. 124, no. 24, pp. 4622-4632, 2018.
[26] J. K. Lue et al., "Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes," Blood Cancer Journal, vol. 14, no. 1, p. 178, 2024.
[27] A. Mehta, A. Verma, G. Gupta, R. Tripathi, and A. Sharma, "Double hit and double expresser diffuse large B cell lymphoma subtypes: discrete subtypes and major predictors of overall survival," Indian Journal of Hematology and Blood Transfusion, vol. 36, no. 4, pp. 627-634, 2020.
[28] T. Strüßmann et al., "Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantation: a single‐centre retrospective experience," British journal of haematology, vol. 198, no. 4, 2022. | ||
|
Statistics Article View: 333 PDF Download: 320 |
||